First Quarter 2008 - Issues in Hematology - ION Solutions

More documents

Recommendations

Info

industry insightWhat core competencies did Hospirabring to the acquisition? How havethese competencies benefitedoncology customers?Hospira is proud of our leadership position andbroad portfolio of generic injectables and infusiontherapy products. In addition, we have specializedin the development of medication managementdevices, such as electronic infusion systems forintravenous therapies, for many years. Together,our pharmaceuticals and devices allow us toadvance wellness for patients and help addressthe healthcare industry’s key needs.want to continue our focus on genericinjectables, while moving beyond small-moleculegenerics into the development of novelpharmaceutical compounds in oncologyand acute-care therapeutics.Our strengths benefi t oncology customers byallowing us to bring more products and moresolutions to the market. As we move forward,oncology clinicians and patients will also benefi tfrom Hospira’s proprietary products and portfoliogrowth. Altogether, we continue to look for waysto be part of the solution for patients, cliniciansand the healthcare industry as a whole.When offering injectable pharmaceuticals, it isextremely important to offer a broad portfolio ofpharmaceuticals, and Hospira has demonstrateda history of consistently producing high-qualityproducts at higher volumes and at a faster ratethan other companies. In addition, Hospira’sclinical development capabilities are strong andimportant to our strategy. Looking forward, weHow has the acquisition of Mayne Pharmamade Hospira become more competitiveboth globally and in the oncology market?Traditionally, more than 90% of ourpharmaceutical sales have come from NorthAmerica, but we are now focusing on healthcareneeds worldwide. With a more balancedoncologistics volume 7, issue 1 - spring 2008 8
oncologistics industry insightglobal portfolio, Hospira currently recognizesapproximately 30% of our revenue from outsideof North America.oncologists and their patients. With our diversifi edapproach, we can offer a number of products andsolutions to oncology customers.Going forward, the largest percentage of saleswill likely continue to come from the U.S., sinceit is the largest market in the world. But, Hospirawill maintain a much broader presence outsidethe U.S., specifi cally in Europe and the Asia-Pacifi c region, where we are building on Mayne’shistoric strength. As we expand our portfolioof pharmaceutical products, we can build andsolidify our offering to oncology patients andclinicians going forward.Eventually, proprietary pharmaceuticals andbiosimilar therapies will comprise a largerpart of our oncology offering. Hospira’sinvestments in biosimilars and the launchof Retacrit (epoetin zeta), our biosimilarerythropoietin, in Europe, where there is asubstantial oncology population, are improvingpatient access to this important treatment.A number of additional oncology-focusedbiosimilar programs are currently underway.What is Hospira’s position within the genericmarket today?We currently lead the generic injectables industryglobally. (Currently, we do not compete in thebroader oral/solids generic markets.) Prior tothe Mayne acquisition, Hospira already heldthe leading position in the U.S. for genericinjectables, even without an oncology portfolio.With the acquisition, the company now hasglobal leadership in this area across all businesssegments. Moving forward, we strive to betterserve the oncologists’ needs, as well as tomaintain and grow our offering outside the U.S.Where do you see Hospira in the next 5 to 10years in the oncology market? What wouldyou like to see Hospira accomplish?Oncology is a very important therapeutic segmentwith growing patient needs, and our vision isfor Hospira to consistently bring products ofincreasing value to people worldwide who aredealing with cancer.As a diversifi ed healthcare company specializingin both drugs and devices, we will continuebringing medication management, infusiontherapy and pharmaceutical products toIn short, we are working to leverage ourdiversifi ed product development skills acrosspharmaceuticals and medication delivery devicesto bring an increased number of effectiveproducts to the oncology market.WITH THE RECENTLAUNCH OF GENERICIRINOTECAN IN THE U.S.,PATIENTS WITH COLON ORRECTAL CANCER WHOSEDISEASE HAS RECURRED ORPROGRESSED FOLLOWINGTHERAPY WITH OTHERTREATMENTS NOW HAVEANOTHER VIABLE TREATMENTOPTION, AT A DRAMATICALLYREDUCED COST.oncologistics 9
Page 2 and 3: C O M I N G S O O NfromCEPHALON ONC
Page 4 and 5: © 2007 Bristol-Myers Squibb Compan
Page 6 and 7: industry insightHOSPIRA’S INCREAS
Page 10 and 11: industry insightWhat differentiates
Page 12 and 13: XELODAEfficacy that makes a differe
Page 14 and 15: Brief summary of prescribing inform
Page 16 and 17: oncologistics volume 7, issue 1 - s
Page 20 and 21: IV IRON SUPPORTTHROUGHOUT CHEMOTHER
Page 22 and 23: established, and the test dose has
Page 24 and 25: eimbursement watchoncologistics vol
Page 26 and 27: eimbursement watch14236132158151241
Page 28 and 29: eimbursement watchon a coverage top
Page 30 and 31: drug updateTHESE STUDIESDEMONSTRATE
Page 32 and 33: drug updateoncologistics volume 7,
Page 34 and 35: POWER ANDPERFORMANCEVIDAZA hits MDS
Page 36 and 37: drug updateBased on recent findings
Page 38 and 39: drug updatehad been met. Median OS
Page 40 and 41: drug update(PDGF-ß), FLT-3, RET, a
Page 42 and 43: FURTHER PROGRESS IN THE TREATMENT O
Page 46 and 47: nurse’s forumOUTPATIENT MANAGEMEN
Page 48 and 49: nurse’s forumoncologistics volume
Page 50 and 51: oncologistics eye on ionEYE on IONG
Page 52 and 53: Note for printer: NOVARTIS 2PG INSE
Page 55 and 56: “ ION provides me with a better v

First Quarter 2008 - Issues in Hematology - ION Solutions

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?